Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Advanced Life Sciences Announces Outcome Of FDA's Anti-Infective Drugs Advisory Committee Review Of Restanza(TM) (cethromycin)
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced that the FDA"s Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee voted that Restanza did not demonstrate efficacy in the treatment of CAP (3 positive, 11 negative, 1 abstaining).

Overall Cardiovascular Safety Of Rosiglitazone Confirmed In 5 1/2-Year Study
Results of the long-awaited Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study were presented here in a symposium at the American Diabetes Association"s 69th Scientific Sessions. The results are being simultaneously published online in The Lancet.
News of the day
Nearly Two Thirds Of Adults In UK Don't Do Enough Exercise, Survey
A survey of UK adults found that nearly two thirds are risking their health by not doing enough exercise and putting themselves at greater risk of
Health Insurance

Multidisciplinary Cancer Congress

ECCO 15 - ESMO 34 will take place at the ICC Berlin - Internationales Congress Centrum, Messedamm 22, D-14055 Berlin, Germany (http://www.icc-berlin.de) from Sunday 20 September to Thursday 24 September 2009. ECCO 15 - ESMO 34 will build on the success of the previous ECCO (European Cancer Conference) and ESMO (European Society for Medical Oncology) conferences. It provides a unique European forum for presentations of cutting-edge research from experimental and clinical oncologists, epidemiologists and cancer nurses. Over 15,000 scientists, doctors, nurses, patients, carers and industry representatives are expected to attend. More than 100 experts in different cancer fields have developed a wide-ranging and exciting congress programme, with large numbers of reports of translational research and first reports from high quality phase III clinical trials. In addition, for the first time there will be an "oncopolicy" track; this has been introduced to help inform European policy on cancer and to ensure its place at the top of the EU health and research policy agenda. Mary Rice ECCO-the European CanCer Organisation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009